Chacruna Institute for Psychedelic Plant Medicines is a registered California 501(c)(3) non-profit organization (EIN 84-3076078). We are a community-oriented organization run by a small staff of experts and enthusiastic volunteers who work to bring education and cultural understanding about psychedelic plant medicines to a wider audience. We promote a bridge between the ceremonial use of sacred plants and psychedelic science and envisage a world where plant medicines and other psychedelics are preserved, protected, and valued as part of our cultural identity and integrated into our social, legal, and health care systems.
Help us to achieve our mission! From our beginnings in 2017, we have stood apart from other psychedelic education and advocacy organizations by pioneering initiatives that support and provide a platform for diverse voices, including women, queer people, people of color, Indigenous people, and the Global South. In efforts to address the lack of diverse representation in the expanding psychedelic landscape, we centered our mission around the empowerment of marginalized voices to foster cultural and political reflections on topics like race, gender, and sexuality in psychedelic science. We believe now more than ever, given the current social and political climate, our work is critical to the future of psychedelic healing for humanity.
Please become a member so that you are able to help Chacruna, yourself, and the world. Support of any amount helps this cause and allows us to provide psychedelic education to anyone who wants to access it.
This excerpt from the book Fly Agaric: A Compendium of History, Pharmacology, Mythology, & Exploration explores the wonderous amanita muscaria mushroom. While many people have considered this mushroom to be dangerous to human health, this essay explores the medicinal therapeutic benefits that may come from consuming it. Kevin Feeney explains its history and analyzes studies that have been conducted surrounding the human consumption of this fungus.
The growth of quantitative ayahuasca research has failed to account for the essential impact of context on study participants. To address this issue, T.J. Wolfe and S. Ruffell, et.al. employed a heuristic study to further explore the phenomenology of the ayahuasca experience in a traditional setting.
When someone is diagnosed with a severe, life-threatening illness, the affected individual may begin to ask several existential questions. The author, Lucas Maia, PhD, summarizes his findings from his doctoral thesis which studied the ritual use of ayahuasca and its therapeutic potential for those facing and fearing death.
Kelan Thomas writes about a new psilocybin group therapy clinical trial for demoralized AIDS survivors that was recently published by Chacruna board member Dr. Brian Anderson.
Dr.’s Aryan Sarparast, Chris Stauffer, Kelan Thomas, and Benjamin Malcolm, recently published the first systematic review of drug interactions between psychiatric medications and psychedelics: “Drug-drug interactions between psychiatric medications and MDMA or psilocybin: A systematic review.” In this article, the authors offer a synopsis of their systematic review.
The rise in popularity of peyote has unfortunately led to overharvesting which consequently poses a great risk for the future of the species. With the increasing need to protect peyote, synthetic mescaline may offer an alternative gateway into this experience that is bereft of issues regarding sustainability. This article summarizes the chemical composition and production of synthetic mescaline.